Compiled by the SIO Research Committee · August 2026

Each month, the SIO Research Committee reviews recently published integrative oncology literature and shares highlights with the broader membership. This month, we reviewed three articles in an open, journal-club-style discussion and highlighted two studies selected by member vote: a pragmatic controlled trial examining integrative oncology outcomes in young adults with cancer, and a nurse-led yoga program tested against usual care in women with gynecologic cancer. A third article, a large randomized trial of mistletoe extract in advanced pancreatic cancer, generated substantial discussion around methodology and real-world applicability and is summarized briefly below.

Integrative Oncology Research:

The SIO Research Committee selected three papers this month for research highlights. A pragmatic, prospective controlled trial published in Medical Oncology found that young adults (ages 18–45) receiving integrative oncology care showed less pronounced improvement in quality-of-life outcomes than older patients, despite being highly engaged and easy to build rapport with — pointing to adherence, not receptivity, as the key barrier (see full review below). A single-blind RCT published in the International Journal of Nursing Studies found that a 6-week nurse-led yoga program significantly reduced cancer-related fatigue and psychological distress, with effects persisting at one month, in women with gynecologic cancer undergoing chemotherapy or chemoradiotherapy — though overall health-related quality of life did not significantly improve (see full review below).

The Empty Half of the Glass: Why Integrative Oncology Is Harder to Deliver to Young Adults with Cancer

Medical Oncology, 2026 Jul  ·

Study type

Prospective, pragmatic, preference-controlled trial (single center, Israel). Patients referred to an integrative oncology service by their oncology providers underwent a ~1-hour integrative physician intake, followed by individualized weekly treatment. Outcomes (ESAS, EORTC QLQ-C30, MYCaW) were assessed at baseline, 6 weeks, and 12 weeks. The study compared highly adherent patients (weekly treatment) to low-adherence patients (one to two visits), and separately compared younger adults (ages 18–45) to older patients.

Background

Most integrative oncology outcomes research is not stratified by age, despite growing recognition that adolescent and young adult (AYA) cancer patients face distinct psychosocial burdens (fertility, identity, career disruption, body image, social isolation) not well captured by instruments developed for older populations. This study is among the first from a real-world integrative oncology service to explicitly compare outcomes and adherence patterns between young adult and older patients.

Key results

• Adherence gap: of more than 200 eligible patients, only 180 (about 74%) had both baseline and 6-week data; attrition was a central theme of the discussion.
• Age effect: young adult patients showed less pronounced improvement in outcomes between baseline and 6 weeks than older patients, despite being described as highly communicative and easy to build rapport with.
• Adherence, not receptivity, appears to be the barrier: the author’s interpretation is that engagement and openness among young adults do not translate into sustained weekly attendance, likely reflecting competing life priorities, ambiguity around informal caregiver roles, and travel/logistic burden.

Strengths & caveats

• Strength: addresses a genuinely understudied population — both young adult and geriatric patients remain data-sparse in integrative oncology outcomes research.
• Strength: real-world, pragmatic design across seven geographic treatment sites reflects everyday clinical delivery rather than a controlled efficacy setting.
• Caveat: roughly a quarter of eligible patients were excluded from analysis due to missing follow-up data; whether this attrition biased results toward or against the observed age effect is unresolved.
• Caveat: outcome instruments used were developed for general or older adult cancer populations and may not capture domains most salient to young adults (per the NCCN AYA framework), potentially underestimating benefit in this subgroup rather than reflecting a true lack of effect.
• Caveat: a related literature discussion (the MYRIAD trial) reinforced that pediatric/adolescent mindfulness interventions require age-specific tailoring rather than direct adaptation of adult protocols — a caution likely relevant to integrative oncology programming for young adults more broadly.

Bottom line: A real-world reminder that engagement is not the same as adherence. Programs serving young adults with cancer may need tailored outcome measures, flexible delivery (including telehealth), and proactive re-engagement strategies rather than simply offering the same weekly model used with older patients.

Can Nurses Deliver Yoga? A Randomized Trial in Gynecologic Cancer

International Journal of Nursing Studies, 2026 Jun  ·

Study type

Assessor-blinded, two-arm, 1:1 parallel-group RCT (single tertiary center, Jinan, China). Women with gynecologic cancer receiving chemotherapy or chemoradiotherapy were randomized to a 6-week nurse-led yoga program plus usual care, or usual care alone. Outcomes were assessed at baseline (T0), end of intervention (T1), and 1-month follow-up (T2), and analyzed using generalized estimating equations.

Background

Yoga carries a Category 1 NCCN recommendation for cancer-related fatigue and a weak ASCO/SIO recommendation, but supporting evidence is overwhelmingly drawn from breast cancer populations delivered by yoga specialists. This trial is among the first to extend the evidence base to gynecologic cancer and to test a nurse-delivered (rather than specialist-delivered) model — a potentially more scalable approach where resources are constrained.

Key results

• Primary outcome: cancer-related fatigue was significantly reduced in the intervention group at both T1 and T2, with effects persisting a month after the program ended.
• Secondary outcomes: psychological distress was also significantly reduced at T1 and T2. Overall health-related quality of life did not significantly differ between arms, though physical well-being (T1) and functional well-being (T2) subscales improved significantly.
• Pattern: benefits were symptom-specific rather than global — a dissociation the committee noted is common in supportive care trials and worth further study.

Strengths & caveats

• Strength: one of the first RCTs to extend yoga evidence beyond breast cancer into a gynecologic cancer population, with durable (1-month) fatigue and distress benefits.
• Strength: if truly deliverable by general nursing staff, a nurse-led model would meaningfully lower cost and improve scalability versus specialist-led yoga programs.
• Caveat — the committee’s central concern: the manuscript does not report how many nurses delivered the intervention or describe their training. Committee members (Ting Bao, Ana Maria Lopez, Dori Beeler, Linda Carlson) discussed evidence suggesting the program was delivered by a single, extensively yoga-trained nurse/registered yoga instructor rather than a broader cohort of generalist nurses — which would make the “nurse-led” framing potentially overstated and limit generalizability to typical nursing environments with less specialized staff.
• Caveat: single-center, single-country design; no active/attention control (usual care only); heterogeneous population (mixed diagnoses and treatment regimens); short follow-up; modest effect sizes.

Clinical takeaways

• Encouraging signal: yoga appears to reduce fatigue and distress in gynecologic cancer patients, consistent with the broader (largely breast-cancer) literature and the 2025 Cochrane review.
• Interpret “nurse-led” cautiously: until delivery details are clarified, this should be read as evidence that a trained yoga instructor embedded in a nursing role can be effective — not yet evidence that any staff nurse can be trained to deliver comparable benefit.
• Watch for follow-up work: a trial training generalist (non-yoga-specialist) nurses to deliver the program would be the logical — and more clinically meaningful — next step.

Bottom line: Encouraging efficacy data for yoga in an understudied gynecologic cancer population, but the committee felt the “nurse-led, scalable” framing likely overstates what was actually tested. Treat the scalability claim with caution pending clarification of who delivered the intervention.

Mistletoe Extract in Advanced Pancreatic Cancer: Quality-of-Life Data from MISTRAL

Palliative Medicine, 2026 · Discussed by the group

This companion quality-of-life analysis to the MISTRAL trial (whose primary survival endpoint data were previously presented at SIO 2024) found no benefit of mistletoe extract (Viscum album) over placebo on quality-of-life measures in patients with advanced pancreatic cancer. The committee agreed the trial’s methodology is rigorous, but the null result sits in tension with prior positive findings on mistletoe and pancreatic cancer published in the European Journal of Cancer. Eran Ben-Arye noted that in real-world anthroposophic practice, mistletoe is typically used as one component of a broader integrative regimen rather than in isolation, which may partly explain the discrepancy with pragmatic clinical experience; questions were also raised about the high steroid dose used in the trial. Ricardo Ghelman cautioned against over-indexing member communications on any single trial given a much larger body of evidence (22 existing systematic reviews on this product family), and proposed a dedicated future session to explore the mistletoe evidence base and its controversies in greater depth.

A Note on Our Review Process

Each month, the SIO Research Committee reviews recently published, high-impact integrative oncology literature during our regular committee meeting. Rather than assigning a single presenter per article, we discuss each paper together in an informal, journal-club-style format — members with relevant expertise or interest are especially encouraged to speak up, and any member is welcome to do brief pre-reading ahead of time. At the end of discussion, the group votes on which article(s) to feature in that month’s Research Highlights, social media content, and podcast material. We aim to share work that is methodologically sound and clinically meaningful, and to provide honest context — including where a study’s framing may outpace what the data actually show. We welcome article nominations from members for future monthly reviews.

References

1. Ben-Arye E, Samuel S, Turgeman I, Samuels N, Stein N, Gressel O. Integrative oncology for young adults with cancer: A prospective pragmatic controlled trial. Medical Oncology. 2026;43(7):196.
2. Ma X, Qi Y, Shang M, Wong CL, Chan RJ, Ho LLK, Chan DNS. Effects of a nurse-led yoga program on cancer-related fatigue, psychological distress, and health-related quality of life among women with gynecological cancer: A single-blind randomized controlled trial. International Journal of Nursing Studies. 2026 Jun;178:105389. doi: 10.1016/j.ijnurstu.2026.105389.
3. Wode K, Björ O, Klein R, Elander NO, Fransson P, Henriksson R, Sharp L, Scheibling U, Johansson B, Hök Nordberg J, Kienle GS. Mistletoe extract in patients with advanced pancreatic cancer: Health-related quality of life in a double-blind, randomized, placebo-controlled trial (MISTRAL). Palliative Medicine. 2026;40(7):1059–1076. doi: 10.1177/02692163261437609.